2021 年 12 月至 2023 年 3 月期间日本的 SARS-CoV-2 N 抗体血清流行率。

IF 2.5 4区 医学 Q3 INFECTIOUS DISEASES
Seiya Yamayoshi, Etsuko Nagai, Keiko Mitamura, Masao Hagihara, Ryo Kobayashi, Satoshi Takahashi, Akimichi Shibata, Yoshifumi Uwamino, Naoki Hasegawa, Asef Iqbal, Isamu Kamimaki, Kiyoko Iwatsuki-Horimoto, Tokiko Nagamura-Inoue, Yoshihiro Kawaoka
{"title":"2021 年 12 月至 2023 年 3 月期间日本的 SARS-CoV-2 N 抗体血清流行率。","authors":"Seiya Yamayoshi, Etsuko Nagai, Keiko Mitamura, Masao Hagihara, Ryo Kobayashi, Satoshi Takahashi, Akimichi Shibata, Yoshifumi Uwamino, Naoki Hasegawa, Asef Iqbal, Isamu Kamimaki, Kiyoko Iwatsuki-Horimoto, Tokiko Nagamura-Inoue, Yoshihiro Kawaoka","doi":"10.1017/S0950268824000141","DOIUrl":null,"url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 in China and rapidly spread worldwide, leading to a pandemic. The threat of SARS-CoV-2 is subsiding as most people have acquired sufficient antibodies through vaccination and/or infection to prevent severe COVID-19. After the emergence of the omicron variants, the seroprevalence of antibodies against the N protein elicited by SARS-CoV-2 infection ranged from 44.4% to 80.2% in countries other than Japan. Here, we assessed the seroprevalence in Japan before and after the appearance of omicron variants. Serosurveillance of antibodies against N was conducted between December 2021 and March 2023 in Japan. In total, 7604 and 3354 residual serum or plasma samples were collected in the Tokyo metropolitan area and Sapporo, respectively. We found that the seroprevalence in representative regions of Japan increased approximately 3% to 23% after the emergence of the omicron variants. We also found higher seroprevalence among the young compared with the elderly. Our findings indicate that unlike other countries, most of the Japanese population has not been infected, raising the possibility of future SARS-CoV-2 epidemics in Japan.</p>","PeriodicalId":11721,"journal":{"name":"Epidemiology and Infection","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894890/pdf/","citationCount":"0","resultStr":"{\"title\":\"Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.\",\"authors\":\"Seiya Yamayoshi, Etsuko Nagai, Keiko Mitamura, Masao Hagihara, Ryo Kobayashi, Satoshi Takahashi, Akimichi Shibata, Yoshifumi Uwamino, Naoki Hasegawa, Asef Iqbal, Isamu Kamimaki, Kiyoko Iwatsuki-Horimoto, Tokiko Nagamura-Inoue, Yoshihiro Kawaoka\",\"doi\":\"10.1017/S0950268824000141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 in China and rapidly spread worldwide, leading to a pandemic. The threat of SARS-CoV-2 is subsiding as most people have acquired sufficient antibodies through vaccination and/or infection to prevent severe COVID-19. After the emergence of the omicron variants, the seroprevalence of antibodies against the N protein elicited by SARS-CoV-2 infection ranged from 44.4% to 80.2% in countries other than Japan. Here, we assessed the seroprevalence in Japan before and after the appearance of omicron variants. Serosurveillance of antibodies against N was conducted between December 2021 and March 2023 in Japan. In total, 7604 and 3354 residual serum or plasma samples were collected in the Tokyo metropolitan area and Sapporo, respectively. We found that the seroprevalence in representative regions of Japan increased approximately 3% to 23% after the emergence of the omicron variants. We also found higher seroprevalence among the young compared with the elderly. Our findings indicate that unlike other countries, most of the Japanese population has not been infected, raising the possibility of future SARS-CoV-2 epidemics in Japan.</p>\",\"PeriodicalId\":11721,\"journal\":{\"name\":\"Epidemiology and Infection\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894890/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epidemiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/S0950268824000141\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0950268824000141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)于 2019 年在中国出现,并迅速蔓延至全球,导致大流行。由于大多数人已通过接种疫苗和/或感染获得足够的抗体来预防严重COVID-19,SARS-CoV-2的威胁正在减弱。在 Omicron 变种出现后,在日本以外的国家,SARS-CoV-2 感染引起的 N 蛋白抗体的血清流行率从 44.4% 到 80.2% 不等。在此,我们评估了日本在奥米克龙变种出现之前和之后的血清流行率。日本在 2021 年 12 月至 2023 年 3 月期间进行了 N 抗体血清监测。在东京首都圈和札幌分别共采集了 7604 份和 3354 份残留血清或血浆样本。我们发现,在奥米克变种出现后,日本代表性地区的血清流行率增加了约 3% 至 23%。我们还发现年轻人的血清流行率高于老年人。我们的研究结果表明,与其他国家不同的是,日本的大部分人口尚未受到感染,这就增加了日本未来发生 SARS-CoV-2 流行病的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 in China and rapidly spread worldwide, leading to a pandemic. The threat of SARS-CoV-2 is subsiding as most people have acquired sufficient antibodies through vaccination and/or infection to prevent severe COVID-19. After the emergence of the omicron variants, the seroprevalence of antibodies against the N protein elicited by SARS-CoV-2 infection ranged from 44.4% to 80.2% in countries other than Japan. Here, we assessed the seroprevalence in Japan before and after the appearance of omicron variants. Serosurveillance of antibodies against N was conducted between December 2021 and March 2023 in Japan. In total, 7604 and 3354 residual serum or plasma samples were collected in the Tokyo metropolitan area and Sapporo, respectively. We found that the seroprevalence in representative regions of Japan increased approximately 3% to 23% after the emergence of the omicron variants. We also found higher seroprevalence among the young compared with the elderly. Our findings indicate that unlike other countries, most of the Japanese population has not been infected, raising the possibility of future SARS-CoV-2 epidemics in Japan.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Epidemiology and Infection
Epidemiology and Infection 医学-传染病学
CiteScore
4.10
自引率
2.40%
发文量
366
审稿时长
3-6 weeks
期刊介绍: Epidemiology & Infection publishes original reports and reviews on all aspects of infection in humans and animals. Particular emphasis is given to the epidemiology, prevention and control of infectious diseases. The scope covers the zoonoses, outbreaks, food hygiene, vaccine studies, statistics and the clinical, social and public-health aspects of infectious disease, as well as some tropical infections. It has become the key international periodical in which to find the latest reports on recently discovered infections and new technology. For those concerned with policy and planning for the control of infections, the papers on mathematical modelling of epidemics caused by historical, current and emergent infections are of particular value.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信